Learn more about Peter Attia’s digital program
Transcript — The Drive — Dave Feldman
Transcript of episode 19 of The Drive with Peter Attia, released October 8, 2018.
#22 – Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins
“Here’s something that’s going to shock you: in an average person, anywhere from 30 to 60 percent of the cholesterol in that LDL particle arrived via an HDL particle.” –Tom Dayspring
#240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.
“HDL cholesterol itself is not directly and causally protective against atherosclerotic cardiovascular disease.” —Dan Rader
#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring
#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB
“Not everybody dies from atherosclerosis, but… everybody dies with it.” —Peter Attia
#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
#203 – AMA #34: What Causes Heart Disease?
“Not everybody dies from atherosclerosis, but… everybody dies with it.” — Peter Attia
#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
“One of the things that is so dangerous about this disorder is that the plaque that you get in FH is a soft plaque.” —John Kastelein
The straight dope on cholesterol – Part I
Welcome to a topic near and dear.